-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

496 ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Sunday, December 8, 2024: 10:15 AM

Cesar Rodriguez, MD1*, Michal Mielnik, MD2*, Dickran Kazandjian, MD3, Wojt Janowski, MD4*, Michael S.Y. Low, MBBS, PhD5, Matthew Pianko6, Junichiro Yuda, MD, PhD7*, Carrie Van Der Weyden, MBBS (Hons), FRACP, FRCPA8*, Larry D Anderson Jr., MD, PhD9, Rahul Banerjee, MD, FACP10, Laura Rosinol Dachs, MD PhD11*, Claudio Cerchione, MD12, Malin Hultcrantz, MD13, Anita D'Souza, MD, MS14*, Amandeep Godara15, Ariel Grajales-Cruz16*, Ziyi Jin, MS17*, Akshanth R Polepally, PhD18*, Aarif Ahsan17*, Shane Lee, MS17*, Kristin D'Amico17*, Orlando Bueno, MD, PhD17, Chetasi Talati, MD19*, Anders Erik Svensson, MD17*, Leanne Fleming, PhD17*, Katja C. Weisel, MD20, Marek Hus21* and Peter M. Voorhees, MD22

1Division of Hematology-Oncology, Department of Internal Medicine, Mount Sinai, New York, NY
2Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
3Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
4Calvary Mater Newcastle, Newcastle, NSW, Australia
5School of Clinical Sciences at Monash Health, Monash University, Clayton, AUS
6Rogel Cancer Center, University of Michigan, Ann Arbor, MI
7National Cancer Center Hospital East, Kashiwa, Japan
8Department of Hematology, Peter MacCallum Cancer Center, Melbourne, VIC, AUS
9Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
10University of Washington, Fred Hutchinson Cancer Center, Seattle, WA
11Hematology Department, Hospital Clinic de Barcelona and Insitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
12Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola (FC), Italy
13Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
14Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
15Huntsman Cancer Institute, Salt Lake City, UT
16Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
17AbbVie Inc., North Chicago, IL
18AbbVie Inc., Danville, CA
19AbbVie, Inc., North Chicago, IL
20Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
21Department of Hemato Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lubin, Poland
22Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC

Introduction

ABBV-383 is a fully human bispecific antibody that targets B-cell maturation antigen (BCMA) and CD3 on the surface of multiple myeloma (MM) cells and T cells, respectively, resulting in T-cell activation and selective destruction of BCMA-positive MM cells. ABBV-383 is composed of a bivalent BCMA-binding domain with high avidity, a low-affinity CD3-binding domain designed to mitigate cytokine release with potential for minimal T-cell exhaustion, and a present but silenced Fc tail resulting in an extended half-life and convenient dosing interval (every 4 weeks [Q4W]). These characteristics potentially result in a manageable safety profile and robust efficacy. ABBV-383 monotherapy showed promising results in heavily pretreated patients (pts) with relapsed or refractory MM in a phase 1 first-in-human dose-escalation study (NCT03933735; Rodriguez et al. JCO 2024;42[suppl 16]:7531). Daratumumab could add beneficial immunomodulatory effects to treatment with ABBV-383, by eliminating immunosuppressor cells and reducing T-cell exhaustion. The current study (Kilimanjaro; NCT05259839) evaluates the hypothesis that combining ABBV-383 with daratumumab and dexamethasone (Dd) may be tolerable and result in enhanced antitumor activity in heavily pretreated pts with MM.

Methods

This open-label, multicenter, phase 1b, dose-escalation and -expansion study is evaluating safety, preliminary efficacy, pharmacokinetics, and the RP2D of ABBV-383 in different combination regimens; here we report on ABBV-383 plus Dd. The study is being conducted at 47 centers in 7 countries globally. Enrolled pts are adults (≥18 years) who have an ECOG performance status ≤2, MM progression during or after the last treatment, and received ≥3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory drug. Prior anti-CD38 monoclonal antibody (mAb) exposure was allowed (>90 days of first dose of study drug). Pts received 20 mg, 40 mg, or 60 mg intravenous ABBV-383 Q4W. For the first ABBV-383 dose, pts were hospitalized for a minimum of 24 hours; subsequent doses were administered in an outpatient setting until progressive disease. The daratumumab dose was 1800 mg, weekly for cycles 1–2 and then at standard reduced frequency; the dexamethasone dose was 40 mg weekly. Responses were investigator assessed per IMWG 2016 criteria.

Results

As of May 15, 2024, 74 pts were enrolled and treated across 3 dose levels of ABBV-383 plus Dd. Median age was 69 years (range 39–89) and 45 (61%) pts were male. The majority of pts were White (n=65, 88%), 6 (8%) were Asian, and 3 (4%) were Black or African American. R-ISS at study entry was I in 18 (25%) pts, II in 26 (36%), and III in 15 (21%). Pts had received a median of 4 (range 3–9) prior lines of therapy; 70% were exposed to prior anti-CD38 mAb therapy. Forty-two (57%) pts were refractory to prior anti-CD38 mAb therapy, 34 (46%) were refractory to the most recent MM therapy, and 32 (43%) were triple-class refractory. After a median follow-up of 5 months (range 0–14), 48 (65%) pts remained on therapy; the majority of study drug discontinuations were due to progressive disease (n=14, 19%). Cytokine release syndrome (CRS) occurred in 20 (27%) pts. The majority of CRS events were grade 1 (n=8, 11%) or 2 (n=9, 12%); 3 (4%) pts had grade 3 events. Other most common treatment-emergent adverse events (AEs) included (any grade/grade 3–4) neutropenia (39%/38%), anemia (24%/18%), fatigue (22%/0%), and thrombocytopenia (30%/18%). Immune effector cell-associated neurotoxicity syndrome was reported in 2 (3%) pts total. Most common serious AEs were CRS (20%), COVID-19 pneumonia (7%), and pneumonia (5%). Twelve deaths occurred during the study to date; the most common cause was disease progression (n=5, 7%). At the time of data cutoff, 60 pts were evaluable for disease assessment. The aggregate overall response rate (ORR) for the total evaluable population was 70% (42/60). ORRs were 50% (7/14) in the 20-mg Q4W ABBV-383 cohort at a median follow-up of 1 month (range 0–14), 74% (26/35) in the 40-mg cohort at a median follow-up of 4.4 months (1–10), and 82% (9/11) in the 60-mg cohort at a median follow-up of 5.6 months (1–6). Median progression-free survival was not reached at time of analysis.

Conclusion

Preliminary data suggest ABBV-383 in combination with Dd is tolerable. Overall rates of CRS were low and early response rates were promising in the investigated population of heavily pretreated pts with MM.

Disclosures: Rodriguez: Janssen: Consultancy; Takeda: Consultancy; Sanofi: Consultancy; BMS: Consultancy; AbbVie: Consultancy; Johnson and Johnson: Consultancy; Amgen: Consultancy; Karyopharm Therapeutics: Consultancy. Mielnik: Eli Lilly: Honoraria; Sanofi: Honoraria; MSD: Honoraria; Bristol-Myers Squibb: Honoraria; Bristol-Myers Squibb - Celgene: Honoraria; Novartis: Honoraria; Johnson & Johnson - Janssen: Consultancy, Honoraria, Other: travel; AbbVie: Consultancy, Honoraria; GSK: Consultancy, Honoraria. Kazandjian: MJH Life Sciences: Honoraria; Aptitude Health: Honoraria; NCI/NIH, FDA, MMRF, DoD-PROMETHEUS (Murtha Cancer Center Research Program), Amgen, BMS/Celgene, Janssen,: Research Funding; Dedham Group: Consultancy; Plexus: Honoraria; Alphasights: Consultancy; Curio Science: Honoraria; Karyopharm Therapeutics: Honoraria, Research Funding, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Aperture Medical Technologies: Honoraria, Other: served on independent data monitoring committees (IDMC); Arcellx: Honoraria, Other: served on independent data monitoring committees (IDMC); Magnolia: Honoraria; MJH Life Sciences: Honoraria; Bridger Consulting Group: Consultancy; BMS: Honoraria; MMRF: Honoraria. Janowski: Janssen, Pfizer, Beigene: Consultancy. Pianko: Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi: Honoraria; Janssen, Pfizer: Consultancy; AbbVie, Ascentage, Bristol Myers Squibb, Janssen, Nektar, Pfizer, Regeneron, Sanofi: Research Funding. Yuda: Incyte: Research Funding; Janssen: Research Funding; Mitsubishi Tanabe: Research Funding; Sumitomo: Research Funding; BMS: Research Funding; Takeda: Research Funding; Novartis: Research Funding; Genmab: Research Funding; AbbVie: Research Funding; Amgen: Research Funding; Chugai: Research Funding; Daiichi Sankyo: Research Funding; MSD: Research Funding. Van Der Weyden: Kyowa Kirin: Consultancy. Anderson: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Prothena: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: DSMB; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectar Biosciences: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Other: Travel Expenses, Research Funding. Banerjee: Adaptive; BMS; Caribou Biosciences; Genentech; GSK; JNJ / Janssen; Karyopharm; Legend Biotech; Pfizer; Sanofi; SparkCures: Consultancy; Abbvie; JNJ; Novartis; Pack Health; Prothena; Sanofi: Research Funding. Rosinol Dachs: Sanofi: Honoraria, Other: Honoraria for lectures; Janssen, BMS, Takeda, Menarini, Pfizer: Honoraria; GSK: Honoraria, Other: Honoraria for lectures; Janssen Pharmaceutica: Honoraria, Other: Honoraria for lectures and meeting travel support; Amgen: Honoraria, Other: Educational lectures. Cerchione: Karyopharm: Consultancy; Jazz: Consultancy; Beigene: Consultancy; Astellas: Consultancy; AMGEN: Consultancy; Skyline DX: Consultancy; GSK: Consultancy; Takeda: Consultancy; Curis: Consultancy; Glycomimetics: Consultancy; Immunogen: Consultancy; Janssen: Consultancy; Servier: Consultancy; BMS: Consultancy; Abbvie: Consultancy; GSK: Consultancy, Current holder of stock options in a privately-held company; Sanofi: Consultancy; Pfizer: Consultancy; Oncopeptides: Consultancy; Menarini-Stemline: Consultancy; Karyopharm: Consultancy; Stemline: Consultancy; Abbvie, AMGEN, Astellas, Beigene, BMS, Glycomimetics, GSK, Immunogen, Janssen, Jazz, Karyopharm, Menarini - Stemline, Oncopeptides, Pfizer, Sanofi, Servier, Stemline, Takeda: Other: Advisory board. Hultcrantz: Curio Science LLC, Intellisphere LLC, Janssen, Bristol Myers Squibb, and GlaxoSmithKline: Consultancy, Honoraria; Abbvie, GlaxoSmithKline, SpringWorks Therapeutics, Daiichi Sankyo, Cosette Pharmaceuticals: Research Funding. D'Souza: Kedrion, Pfizer, Janssen, Bristol Myers Squibb, BMS, Janssen, and Prothena.: Consultancy; AbbVie, Sanofi, Novartis, Janssen, Regeneron, Takeda, TeneoBio, Caelum, and Prothena: Research Funding. Godara: Janssen, Sanofi: Consultancy. Grajales-Cruz: Cellectar Biosciences: Honoraria, Other: Data Safety Monitoring/Advisory Board, Research Funding; Janssen: Honoraria, Other: Data Safety Monitoring/Advisory Board; Sanofi: Honoraria, Other: Data Safety Monitoring/Advisory Board; Amgen: Honoraria; Pfizer: Honoraria, Other: Data Safety Monitoring/Advisory Board. Jin: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Polepally: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Ahsan: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Lee: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. D'Amico: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Bueno: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Talati: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Svensson: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Fleming: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Weisel: Amgen: Consultancy, Honoraria, Other: Research grant to institution; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Other: Research grant to institution; GlaxoSmithKline: Consultancy, Honoraria, Other: Research grant to institution; Janssen: Consultancy, Honoraria, Other: Research grant to institution; Sanofi: Consultancy, Honoraria, Other: Research grant to institution; Adaptive Biotechnologies: Consultancy, Honoraria; AstraZeneca: Honoraria; BeiGene: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; Roche Pharma: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Novartis: Honoraria; AbbVie: Other: Research grant to institution; Stemline: Honoraria; Takeda: Consultancy, Honoraria; Regeneron: Consultancy. Hus: AbbVie Inc., Amgen, AstraZeneca, BMS/Celgene, Janssen, GSK, MSD, Novartis, Roche, Oncopeptides, Sanofi, Takeda: Honoraria; Roche: Other: travel expenses; medical writing support; Janssen: Other: travel expenses. Voorhees: Janssen: Consultancy, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Research Funding; AstraZeneca: Consultancy; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lava Therapeutics: Consultancy; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

*signifies non-member of ASH